The main function of thrombocytes (platelets) is to stop bleeding. When a blood vessel is damaged, they stick to the injured wall, become activated, clump together into a plug and provide the surface on which clotting factors build a stable fibrin clot. Beyond this, platelets help fight infection, drive inflammation, release growth factors that repair tissue and influence new blood vessel growth. Unfortunately, they can also help cancer cells spread.
A healthy adult typically has 150,000 to 450,000 platelets per microliter of blood. Many labs use an upper limit of 400,000, so check the range printed on your own report. Each platelet lives about 7 to 10 days. This guide explains how platelets are made, what they do step by step, their functions beyond clotting, how platelet function is tested, and what happens when things go wrong.
What Are Thrombocytes?
Thrombocytes are small, disc-shaped cell fragments, only about 2–3 micrometers across, that circulate in the blood. “Thrombocyte” is the formal medical term, and “platelet” is the everyday one. Human platelets have no nucleus. They still carry mitochondria, some RNA, a flexible internal skeleton and granules packed with signaling molecules. That toolkit lets them change shape, stick, spread and release their contents within seconds of meeting an injury.
At any moment, about a third of the body’s platelets are held in reserve in the spleen, and the rest circulate. Old platelets are cleared mainly by the spleen and liver.
How are platelets formed?
Platelets are made in the bone marrow by very large cells called megakaryocytes. The process, called thrombopoiesis, is controlled mainly by the hormone thrombopoietin (TPO), which the liver makes. Each megakaryocyte extends long branches (proplatelets) into the marrow’s blood vessels, and these break off into thousands of platelets. Together, the marrow produces around a hundred billion new platelets every day to replace those that are used up or age out. You can read more in our guides to platelet production and bone marrow function.
How Platelets Work, Step by Step
Stopping bleeding, called hemostasis, happens in a fast, overlapping sequence:
- Formation and circulation. Resting platelets travel along the edge of the blood flow, close to the vessel wall. Healthy lining cells release substances such as nitric oxide and prostacyclin that keep the platelets inactive.
- Adhesion. When a vessel is injured, collagen beneath the lining is exposed. Von Willebrand factor (VWF) binds to that collagen, and platelets latch onto VWF through their GPIb receptor. They can also bind collagen directly through GPVI.
- Activation. Adhesion switches the platelet on. It changes from a smooth disc into a spiky sphere and releases its granule contents, including ADP, serotonin and calcium. It also makes thromboxane A2. These signals recruit more platelets. This is platelet activation.
- Aggregation. Activated platelets switch on their GPIIb/IIIa receptors, which grab fibrinogen and link platelet to platelet. The result is a loose platelet plug within minutes. This is platelet aggregation.
- Consolidation (secondary hemostasis). The activated platelet surface exposes phosphatidylserine, which provides the platform where clotting factors assemble. This speeds up thrombin production, and thrombin converts fibrinogen into a fibrin mesh that locks the plug in place.
- Clot retraction and healing. Platelets contract and pull the clot tight, drawing the wound edges together. They then release growth factors that start repair. Later, the clot is dissolved (fibrinolysis) once the vessel has healed.
The 7 Key Functions of Thrombocytes
Hemostasis is the classic job, but platelets take part in several other physiological processes:
| Function | What platelets do | Key molecules involved |
|---|---|---|
| 1. Primary hemostasis | Adhere to injured vessel walls and form a plug | GPIb-IX-V, von Willebrand factor, GPIIb/IIIa |
| 2. Secondary hemostasis | Provide the surface where clotting factors assemble | Phosphatidylserine, factor V, fibrinogen |
| 3. Inflammation | Release chemokines and recruit white blood cells | PF4 (CXCL4), RANTES (CCL5), P-selectin |
| 4. Innate immunity | Detect microbes, trap them and support neutrophils | Toll-like receptors (TLR2, TLR4), antimicrobial peptides |
| 5. Tissue repair and wound healing | Release growth factors that stimulate new tissue | PDGF, TGF-β, VEGF, EGF |
| 6. Angiogenesis | Promote or inhibit new blood vessel growth | VEGF (promotes), endostatin (inhibits) |
| 7. Cancer metastasis | Coat circulating tumor cells and help them evade immunity | P-selectin, fibrinogen bridging, TGF-β |
Immune defense: platelets as first responders
Platelets carry Toll-like receptors, the same pattern-recognition sensors found on macrophages. Through them, platelets can detect bacterial products such as lipopolysaccharide. Activated platelets release antimicrobial peptides, bind and trap bacteria, and team up with neutrophils. They present microbes to neutrophils and help trigger neutrophil extracellular traps (NETs), the sticky webs of DNA and proteins that neutrophils cast to snare microbes. Platelets are therefore a link between the clotting system and the immune system. That link also helps explain why severe infections so often cause abnormal clotting and low platelet counts.
Inflammation and tissue repair
The alpha granules inside platelets hold growth factors (PDGF, TGF-β, VEGF, EGF) and inflammatory messengers. Once released at a wound, these recruit white cells, stimulate fibroblasts to lay down new tissue and encourage new capillaries to grow. The same biology can cause harm in chronic inflammation, for example in the build-up of atherosclerotic plaque.
Cancer: a harmful partnership
When cancer cells enter the bloodstream, platelets can coat them. This shield hides the tumor cells from natural killer cells, helps them stick to vessel walls at distant sites and releases TGF-β, which can make them more invasive. Many cancers also activate platelets and the clotting system directly, which is one reason people with cancer have a higher risk of blood clots. Whether antiplatelet drugs have a role in cancer treatment is still being studied. It is not established practice.
When Platelet Function Causes Harm: Thrombosis
The same system that stops you bleeding can cause a blockage in the wrong place. In arteries, the classic trigger is a ruptured cholesterol plaque. Platelets stick to the exposed plaque contents, activate and aggregate exactly as they would at a wound, and form a platelet-rich thrombus that can block blood flow. This is the underlying event in most heart attacks and many strokes, and in blockages of arteries to the legs.
Venous clots, such as deep vein thrombosis, depend more on clotting factors and slow blood flow than on platelets. That’s why they are treated mainly with anticoagulants, while arterial disease is treated mainly with antiplatelet drugs.
How antiplatelet drugs target platelet function
| Drug class | Examples | Step blocked |
|---|---|---|
| COX-1 inhibitor | Aspirin | Thromboxane A2 production (activation and recruitment) |
| P2Y12 inhibitors | Clopidogrel, prasugrel, ticagrelor | The ADP receptor that amplifies activation |
| GPIIb/IIIa inhibitors | Eptifibatide, tirofiban | The final common step of aggregation (used intravenously in hospital) |
| PDE inhibitors | Dipyridamole, cilostazol | Raise platelet cyclic AMP, damping activation |
Each of these drugs lowers the risk of arterial clots, and each raises the risk of bleeding in return. This is why you should never stop or start one without advice. Before surgery, your team will tell you whether and when to pause them.
Platelet Tests: Count, Indices and Function
A complete blood count (CBC) gives the platelet count and usually two platelet indices. When bleeding happens despite a normal count, doctors turn to platelet function tests.
What is mean platelet volume (MPV)?
Mean platelet volume is the average size of your platelets. A typical reference range is about 7.5–11.5 femtoliters, but it varies by lab and analyzer. Young platelets tend to be larger. So a low count with a high MPV suggests the marrow is working hard to replace platelets that are being destroyed, as in immune thrombocytopenia (ITP). A low count with a low or normal MPV points more toward a production problem. Some inherited conditions produce giant platelets.
Immature platelet fraction (IPF)
The immature platelet fraction measures the proportion of newly released, RNA-rich platelets. It works like a reticulocyte count for platelets. A high IPF means the marrow is actively producing, as seen with peripheral destruction. A low IPF alongside a low count suggests marrow failure or suppression, for example after chemotherapy.
Platelet function tests
| Test | What it measures | When it’s used |
|---|---|---|
| PFA closure time (e.g. PFA-100) | Time for platelets to plug a tiny aperture coated with collagen plus epinephrine or ADP, under flow | Screening for von Willebrand disease and platelet function disorders; aspirin prolongs the collagen/epinephrine result |
| Light transmission aggregometry | How well platelets clump in response to ADP, collagen, arachidonic acid, epinephrine and ristocetin | Diagnosing inherited platelet disorders and assessing antiplatelet drug effects |
| Viscoelastic tests (TEG, ROTEM) | Whole-blood clot formation, strength and breakdown over time | Guiding transfusion in surgery, trauma and obstetric bleeding |
| Flow cytometry | Platelet surface glycoproteins and activation markers | Confirming Glanzmann thrombasthenia or Bernard-Soulier syndrome |
| Bleeding time | Time for a standardized small skin cut to stop bleeding | Largely replaced by the tests above because it is poorly reproducible |
How platelet tests differ from PT/INR and PTT
The prothrombin time (PT/INR) and partial thromboplastin time (PTT or aPTT) measure the clotting factors in plasma, not platelets. The PT reflects the extrinsic and common pathways and is used to monitor warfarin. The PTT reflects the intrinsic and common pathways and is used to monitor unfractionated heparin. A person with a severe platelet function disorder can have a completely normal PT and PTT. That’s why both kinds of test are often ordered together as part of a coagulation panel.
What do platelet function test results mean?
A prolonged closure time or reduced aggregation means the platelets aren’t plugging or clumping normally. The pattern across agonists often points to the cause. For example, no aggregation with any agonist except ristocetin suggests Glanzmann thrombasthenia, while a poor response to ristocetin suggests Bernard-Soulier syndrome or von Willebrand disease. Aspirin, other NSAIDs, some antidepressants and even certain supplements can distort results, so tell the lab about everything you take. Results are always interpreted by a specialist alongside your bleeding history.
When Platelets Go Wrong
Platelet dysfunction falls into three broad groups: too few platelets, too many, or a normal number that don’t work properly.
Low platelet count (thrombocytopenia)
| Platelet count (per µL) | Typical significance |
|---|---|
| 150,000–450,000 | Normal range (upper limit varies by lab) |
| 100,000–150,000 | Mild; usually no symptoms |
| 50,000–100,000 | Moderate; bleeding mainly with surgery or trauma |
| 20,000–50,000 | Easy bruising; procedures need planning |
| Below 10,000–20,000 | Risk of spontaneous bleeding, petechiae and, rarely, internal bleeding |
Common causes include immune thrombocytopenia (ITP), chemotherapy and other marrow suppression, liver disease with an enlarged spleen, heavy alcohol use, B12 or folate deficiency, and heparin-induced thrombocytopenia (HIT). A mild fall in platelet count is also common in late pregnancy.
High platelet count (thrombocytosis)
Counts above the upper limit are usually reactive, caused by infection, inflammation, iron deficiency, bleeding or removal of the spleen. Less often, they are clonal, as in essential thrombocythemia and other myeloproliferative neoplasms driven by JAK2, CALR or MPL mutations. Clonal thrombocytosis carries a real risk of both clotting and, at very high counts, bleeding.
Normal count, poor function: inherited vs acquired disorders
Some people bleed easily even though their count is normal, because their platelets don’t work properly.
- Inherited: Glanzmann thrombasthenia (missing or faulty GPIIb/IIIa, so no aggregation), Bernard-Soulier syndrome (missing GPIb, large platelets, poor adhesion), and storage pool and secretion disorders (granules that are empty or don’t release). Von Willebrand disease, the most common inherited bleeding disorder, is technically a factor problem, but it looks similar because platelets can’t adhere without VWF.
- Acquired: far more common. Causes include aspirin, clopidogrel and similar drugs, other NSAIDs, kidney failure (uremia), cardiopulmonary bypass, liver disease and myeloproliferative neoplasms.
Platelets in Treatment: Transfusion, PRP and Donation
Platelet transfusions
Platelets are stored at room temperature (20–24°C) with constant gentle agitation, so they have a short shelf life of about 5 days, extended in some systems with extra bacterial testing or pathogen reduction. In an average adult, one adult dose typically raises the count by roughly 30,000–60,000/µL. Common thresholds are below 10,000/µL to prevent bleeding in stable patients, 50,000/µL before most surgery and higher for neurosurgery. Treatment is always tailored to the patient.
Are platelet transfusions safe?
They are generally safe and often lifesaving, but no transfusion is risk-free. The most common reactions are fever and mild allergic reactions such as hives, which are usually easily managed. Because platelets are stored warm, bacterial contamination is a greater concern than with other blood components. Blood services reduce that risk with bacterial testing or pathogen-reduction technology. Rarer risks include transfusion-related lung injury (TRALI) and, in patients who have many transfusions, antibodies that make later platelet transfusions less effective.
What is platelet-rich plasma (PRP) used for?
Platelet-rich plasma is made by spinning a sample of your own blood to concentrate the platelets, then injecting the concentrate into an injured area. The aim is to deliver a dose of growth factors. PRP is used in sports medicine and orthopedics (tendon injuries, knee osteoarthritis), in wound care and in cosmetic dermatology, including hair loss. The evidence is mixed. PRP appears helpful for some conditions and unproven for others, and preparation methods vary widely between clinics. Because it uses your own blood, the risk of reactions is low, but it is often not covered by insurance.
Who can donate platelets?
Platelets are collected by apheresis. Blood is drawn from one arm and passed through a machine that keeps the platelets and returns the rest to you. It takes longer than a whole-blood donation, typically one and a half to three hours. General eligibility follows whole-blood rules: good health, a minimum age (commonly 17, or 16 with parental consent in some places) and a minimum body weight. Donors are usually asked to avoid aspirin for a couple of days beforehand, because it disables the platelets they would give. Platelet donors can give far more often than whole-blood donors, because platelets regenerate within days. Your local blood service sets the exact limits.
When to See a Doctor
Talk to your doctor if you notice any of the following, as they may indicate a thrombocyte disorder:
- Bruising without a clear cause, or bruises out of proportion to the knock
- Petechiae: tiny red or purple pinpoint spots, often on the lower legs
- Bleeding from minor cuts that goes on much longer than usual
- Heavy menstrual bleeding, or bleeding gums
- Blood in the urine or stool
- Frequent or prolonged nosebleeds
- Unexpected bleeding after dental work or surgery
Seek urgent care for bleeding that won’t stop, a severe headache, or confusion when you have a known low platelet count. The first test is a CBC. Depending on the result, your doctor may add a blood smear, a coagulation panel, platelet function testing or a bone marrow examination. For the bigger picture, see our platelets guide.
Key Takeaways
- The core function of thrombocytes is hemostasis: adhesion, activation, aggregation and support for fibrin clot formation.
- Platelets also take part in immunity, inflammation, wound healing and blood vessel growth, and they can help cancer spread.
- A typical normal count is 150,000–450,000/µL, and labs vary. Platelets live about 7–10 days.
- MPV and IPF help show whether a low count comes from destruction or poor production.
- Platelet function tests (PFA, aggregometry, TEG/ROTEM, flow cytometry) find problems that a normal count and a normal PT/PTT can miss.
Frequently Asked Questions
Are thrombocytes the same thing as platelets?
Yes. “Thrombocyte” is the formal term and “platelet” the everyday one. In birds, fish and reptiles, thrombocytes are true nucleated cells. That distinction matters in comparative hematology but not in human medicine.
What’s a normal platelet count, and does it fluctuate?
Most labs use 150,000–450,000/µL, and some use 150,000–400,000/µL. Counts shift a little with infection, exercise, the menstrual cycle and pregnancy. A single slightly abnormal result is usually repeated before anyone draws conclusions.
Can diet or supplements affect platelets?
Deficiencies of B12 or folate can lower platelet production. Iron deficiency more often raises the count. Fish oil, high-dose vitamin E, garlic and ginkgo may mildly reduce platelet function. No food reliably fixes a significantly low count, which needs medical assessment.
Do antiplatelet drugs like aspirin affect all platelet functions?
Aspirin permanently blocks cyclooxygenase-1 (COX-1) and so stops thromboxane A2 production. The effect lasts for the life of each platelet, about 7–10 days. It mainly weakens aggregation and hemostasis. Its effects on the immune and inflammatory roles of platelets are less clear.
Why do people with cancer often have platelet problems?
Chemotherapy and radiation suppress the marrow and lower platelet production, while many cancers activate platelets and the clotting system. The result can be bleeding risk and clotting risk at the same time, which makes management challenging.
